Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

Clinical trial NCT05800275 · RECRUITING

Trial details

NCT number: NCT05800275
Sponsor: UNICANCER
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Leptomeningeal Metastasis Leptomeningeal Disease HER2-positive Metastatic Breast Cancer

Start date: 2023-12-18
Primary completion: 2026-12-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.